No data to show
XSWX
PPGN
Market cap555mUSD
Apr 09, Last price
14.38CHF
1D
-5.77%
1Q
-49.72%
IPO
-82.08%
Name
PolyPeptide Group AG
Chart & Performance
P/E
—
P/S
1.50
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.90%
Rev. gr., 5y
10.82%
Revenues
339m
+5.72%
Net income
-20m
L-61.97%
CFO
89m
+145.03%
Dividend
Apr 28, 20220.3 CHF/sh
Earnings
Apr 10, 2025
Profile
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 338,688 5.72% | 320,372 14.02% | 280,978 -0.41% | ||||
Cost of revenue | 321,847 | 335,955 | 269,678 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 16,841 | (15,583) | 11,300 | ||||
NOPBT Margin | 4.97% | 4.02% | |||||
Operating Taxes | 1,419 | (6,803) | 200 | ||||
Tax Rate | 8.43% | 1.77% | |||||
NOPAT | 15,422 | (8,780) | 11,100 | ||||
Net income | (19,564) -61.97% | (51,440) -762.29% | 7,767 -83.56% | ||||
Dividends | (9,671) | ||||||
Dividend yield | 1.16% | ||||||
Proceeds from repurchase of equity | 3,265 | ||||||
BB yield | -0.39% | ||||||
| Debt | |||||||
Debt current | 35,715 | 45,706 | 3,566 | ||||
Long-term debt | 82,457 | 91,278 | 30,628 | ||||
Deferred revenue | 99,639 | 23,160 | 7,532 | ||||
Other long-term liabilities | 43,583 | 36,653 | (9,410) | ||||
Net debt | 49,895 | 36,041 | (6,101) | ||||
| Cash flow | |||||||
Cash from operating activities | 89,399 | 36,485 | 5,460 | ||||
CAPEX | (85,751) | (52,897) | (75,099) | ||||
Cash from investing activities | (91,018) | (59,512) | (78,435) | ||||
Cash from financing activities | (25,323) | 84,547 | (26,869) | ||||
FCF | (49,213) | (23,491) | (77,908) | ||||
| Balance | |||||||
Cash | 68,277 | 95,706 | 37,528 | ||||
Long term investments | 5,237 | 2,767 | |||||
Excess cash | 51,343 | 84,924 | 26,246 | ||||
Stockholders' equity | 140,779 | 165,441 | 232,157 | ||||
Invested Capital | 543,240 | 469,776 | 450,319 | ||||
ROIC | 3.04% | 2.74% | |||||
ROCE | 2.82% | 2.36% | |||||
| EV | |||||||
Common stock shares outstanding | 32,968 | 33,004 | |||||
Price | 28.40 62.10% | 17.52 -30.81% | 25.32 -81.52% | ||||
Market cap | 577,599 -30.88% | 835,661 -81.01% | |||||
EV | 613,640 | 829,560 | |||||
EBITDA | 49,555 | 14,886 | 35,326 | ||||
EV/EBITDA | 41.22 | 23.48 | |||||
Interest | 13,848 | 5,623 | 2,091 | ||||
Interest/NOPBT | 82.23% | 18.50% | |||||